Ubs Oconnor LLC Bio Atla, Inc. Transaction History

Ubs Oconnor LLC

$1.59 Billion
Q1 2024

A detailed history of Ubs Oconnor LLC transactions in Bio Atla, Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 209,770 shares of BCAB stock, worth $287,384. This represents 0.05% of its overall portfolio holdings.

Number of Shares

209,770

Holding current value

$287,384

% of portfolio

0.05%

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.88 - $3.46 $55,172 - $101,540	29,347 Added 16.27%	209,770 $721,000
Q4 2023 Feb 14, 2024	SELL	$1.27 - $3.18 $333,119 - $834,110	-262,299 Reduced 59.25%	180,423 $443,000
Q3 2023 Nov 14, 2023	BUY	$1.7 - $3.07 $68,000 - $122,800	40,000 Added 9.93%	442,722 $752,000
Q2 2023 Aug 14, 2023	BUY	$2.83 - $3.87 $1.14 Million - $1.56 Million	402,722 New	402,722 $1.21 Billion
Q1 2023 May 15, 2023	BUY	$2.3 - $8.25 $66,470 - $238,425	28,900 Added 13.37%	245,025 $656,000

Q4 2022 Feb 14, 2023	BUY	$7.63 - $11.01 $794,473 - $1.15 Million	104,125 Added 92.97%	216,125 $0
Q3 2022 Nov 14, 2022	BUY	$2.94 - $11.87 $329,280 - $1.33 Million	112,000 New	112,000 $862 Million

Others Institutions Holding BCAB

# of Institutions

Shares Held

24.8M

Call Options Held

140K

Put Options Held

4.6K

Soleus Capital Management, L.P. Greenwich, CT

4.07M
Shares

$5.57 Million
1.14% of portfolio
Black Rock Inc. New York, NY

2.78M
Shares

$3.81 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

2.1M
Shares

$2.88 Million
0.0% of portfolio
Morgan Stanley New York, NY

1.91M
Shares

$2.62 Million
0.0% of portfolio
Tang Capital Management LLC San Diego, CA

1.47M
Shares

$2.02 Million
0.62% of portfolio

View Full List

About BioAtla, Inc.

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $49.7M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

More about BCAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.

Account